Speaker Profile

Ph.D., SVP, Research & Development and Chief Research & Development Officer, Nektar Therapeutics
Biography

Steve Doberstein leads the discovery, clinical development, and regulatory affairs teams at Nektar and joined the company in January 2010. Prior to joining Nektar, Dr. Doberstein served as Vice President of Research at XOMA, a monoclonal antibody discovery and development company, where he led the discovery and development of multiple antibody drug candidates, from discovery through non-clinical safety, translational medicine and PK/PD. Prior to that, he served as VIce President of Research at Five Prime Therapeutics, a protein and antibody discovery and development company, and Xencor, a leader in protein engineering. He also held senior leadership positions at Exelixis. He received a PhD from the Johns Hopkins University School of Medicine, and was a MDA Postodctoral Fellow at UC Berkeley. Steve also serves as the Chairman of the Board of Nektar India, and represents Nektar to the NIH Public/Private Partnership to Address the Opioid Crisis.

Immunotherapy Showcae: Nektar Therapeutics
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients.

Engaging The IL-15 Pathway In Immuno-oncology
NKTR-255 is an IL-15 receptor agonist designed to stimulate and expand NK cells and promote the survival and expansion of central memory CD8+ T cells. Through optimal engagement of the IL-15 pathway, NKTR-255 enhances formation of long-term immunological memory which may lead to sustained anti-tumor immune response.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!